Total Costb | Cost Diff (mean) | QALYb | QALY Diff | ICER (€/QALY) | Probability of cost effectiveness | |||
---|---|---|---|---|---|---|---|---|
WTP 20,000€ | WTP 25,000€ | WTP 30.000 | ||||||
All sample | ||||||||
Multiple imputation (base case) | ||||||||
UC CPa | 10.68 | 0.0246 | ||||||
MAS CPa | 17.19 | 6.51 | 0.0247 | 0.0003 | 19,325 | 52.39% | 66.45% | 75.36% |
Complete Cases | ||||||||
UC CPa | 12.61 | 0.0245 | ||||||
MAS CPa | 20.03 | 7.42 | 0.0248 | 0.0003 | 24,733 | 36.19% | 47.40% | 60.10% |
Subgroup with symptom presentation | ||||||||
Multiple imputation (base case for subgroup analysis) | ||||||||
UC CPa | 10.35 | 0.0245 | ||||||
MAS CP* | 19.48 | 9.13 | 0.0247 | 0.0002 | 42,322 | 14.09% | 23.92% | 33.15% |
Complete Cases | ||||||||
UC CPa | 12.59 | 0.0245 | ||||||
MAS CPa | 22.97 | 10.45 | 0.0248 | 0.0002 | 48,126 | 11.20% | 17.39% | 24.40% |
Subgroup with direct product request | ||||||||
Multiple imputation (base case for subgroup analysis) | ||||||||
UC CPa | 11.59 | 0.0242 | ||||||
MAS CPa | 11.90 | 0.31 | 0.0248 | 0.0006 | 523 | 96.83% | 97.32% | 97.58% |
Complete Cases | ||||||||
UC CP* | 14.25 | 0.0247 | ||||||
MAS CPa | 13.54 | −0.71 | 0.0249 | 0.0006 | Dominant | 92.60% | 93.69% | 94.49% |